DOSE ESCALATION OF NEXT GENERATION ANTI-CTLA-4 ANTIBODY ONC-392 IN COMBINATION WITH FIXED DOSE OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0

作者：

Hu-Lieskovan, Siwen ^{[1
]}

He, Kai ^{[2
]}

Tang, Mei ^{[3
]}

Chen, Dan ^{[4
]}

Liu, Yang ^{[4
]}

Zheng, Pan ^{[4
]}

Li, Tianhong ^{[5
]}

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Ohio State Univ, Canc Ctr, Columbus, OH 43210 USA

[3] Greater Baltimore Med Ctr, Baltimore, MD USA

[4] OncoC4 Inc, Rockville, MD USA

[5] Univ Calif Davis, Sacramento, CA 95817 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0594

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

594

引用

页码：A622 / A622

页数：1

共 50 条

[1] PHARMACOKINETICS OF FIRST AND REPEATED DOSING OF NON-IRAE-INDUCING ANTI-CTLA-4 MONOCLONAL ANTIBODY ONC-392 IN ADVANCED CANCER PATIENTS
Chou, Hung-Yen
Li, Tianhong
Kelly, Karen
Martinez, Anthony
Joo, Stacy
Tang, Mei
Devenport, Martin
Liu, Yang
Zheng, Pan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A500 - A500
[2] Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
Maker, AV
Yang, JC
Sherry, RM
Topalian, SL
Kannula, US
Royal, RE
Hughes, M
Yellin, MJ
Haworth, LR
Levy, C
Allen, T
Mavroukakis, SA
Attia, P
Rosenberg, SA
JOURNAL OF IMMUNOTHERAPY, 2006, 29 (04) : 455 - 463
[3] MOLECULAR INSIGHTS ON SAFETY AND ANTI-TUMOR ACTIVITY OF A NON-IRAE-INDUCING ANTI-CTLA-4 MONOCLONAL ANTIBODY ONC-392
Liu, Yang
Zhang, Yan
Du, Xuexiang
Liu, Mingyue
Fang, Xianfeng
Mu, Libing
Tevetnitsky, Vadim
Devenport, Martin
Zheng, Pan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A246 - A246
[4] SAFETY AND CLINICAL ACTIVITIES OF THE ACID PH-SENSITIVE ANTI-CTLA-4 MAB ONC-392 IN OVARIAN CANCER PATIENTS
Hays, John
Li, Tianhong
Chen, Hui
Zahrah, George
Frank, Richard
Hamm, John
Markham, Merry-Jennifer
George, Thomas
Whitman, Eric
Goldstein, Mark
He, Kai
Joshi, Rohit
Chen, Dan
Liu, Yang
Zheng, Pan
O'Malley, David
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A591 - A591
[5] Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Sakamuri, Divya
Glitza, Isabella C.
Cuellar, Sonia L. Betancourt
Subbiah, Vivek
Fu, Siqing
Tsimberidou, Apostolia M.
Wheler, Jennifer J.
Hong, David S.
Naing, Aung
Falchook, Gerald S.
Fanale, Michelle A.
Cabanillas, Maria E.
Janku, Filip
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (03) : 671 - 676
[6] A Phase I Dose-Escalation Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Pembrolizumab
Lu, S.
Sun, M.
Ding, L.
Ji, J.
Yang, D.
Gan, X.
Zhao, Y.
Liu, X.
Chen, X.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S379 - S380
[7] A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors
Gu, Shanzhi
de Souza, Paul L.
Shi, Yuankai
Han, Weiqing
Luo, SuXia
Chen, Jing
Day, Daphne
Frentzas, Sophia
Park, John J.
Shao, Guoliang
Wu, Shikai
Fang, Meiyu
Haydon, Andrew Mark
Sun, Sanyuan
Lei, Kaijian
Ding, Luyin
Zuo, Rui
Gan, Xin
Zhao, Yuansheng
Chen, Xiaoxiang
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
Ganju, Vinod
Cooper, Adam
Gao, Bo
Wilkinson, Kate
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
Xu, Jianming
Cui, Jiuwei
Jiang, Haiping
Zeng, Yan
Cong, Xiuyu
CANCER MEDICINE, 2023, 12 (07): : 7762 - 7771
[10] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
Ganju, Vinod
Cooper, Adam
Gao, Bo
Wilkinson, Kate
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →